Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 09, 2022 1:32pm
113 Views
Post# 34667686

RE:Conferences

RE:ConferencesThe two most important cancer conferences of the year are AACR, which took place in April, and ASCO which takes place this year in early June. There are tons of other conferences, as Wino showed, but those two are the big ones. You will notice the link to the AACR one in October that Qwerty noted and of which I was unaware, didn't even have AACR in its link. I am pretty sure now this is what Christian was referring to, as that makes much more sense from a timing perspective, but still not 100% certain.

Sorry to have confused you or anyone else but while we work hard at this, mistakes and misunderstandings happen - it is just part of the human condition and thereforear tof investing as well. But  thanks to the really smart posters here, the mistake was found promptly and corrected. At least I think so since we are still guessing at a lot of this. 

canadapiet wrote: Wow!
I am perplexed, stunned, baffled, speechless and a little bit upset!!! 

We are here allready such a long time, at least the most of the regular boardwriters! There are priviliged people with a boatload of shares who get info in a limited committee and share it with us, great. But without knowing the most important conferences held in "oncology".!!!
Why do a private meeting, but don't get that info?
Why having so much shares in such a speculative sector and for sure even more speculaive company?????
Why invest with that much money wthout even knowing the basics of the sector/niche oncology?????

Unbelievable, but truth!




<< Previous
Bullboard Posts
Next >>